Clinical trial
A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma
NCT06472895 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- July 20, 2024
- Completion date
- December 20, 2027
- Enrollment
- 30 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
renal cell carcinoma